Tailored hydration using ReDS lung‑water monitoring to prevent kidney injury during coronary angiography and intervention
Official title: Clinical Study on Tailored Hydration by Remote Dielectric Sensing System to Prevent Acute Renal Injury in Elderly Patients With Renal Insufficiency After Coronary Angiography
Run by Chinese PLA General Hospital · NCT07394959 · Data updated 2026-11-12
This trial tests whether using a ReDS lung‑water monitor to guide IV fluids can lower the risk of contrast‑induced acute kidney injury in people aged 60 and older with reduced kidney function having coronary angiography or PCI.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 60 Years and up |
| Sex | All |
| Enrollment | 320 (estimated) |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | September 20, 2024 |
| Main results expected | May 31, 2026 |
| Study ends | November 28, 2026 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT07394959 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 60 or older with unstable angina scheduled for coronary intervention who have chronic kidney disease (eGFR between 30 and 90 mL/min) and can provide informed consent.
✕Probably not a fit
Patients with severe renal failure (eGFR <30 mL/min), acute decompensated heart failure, respiratory failure, recent contrast exposure, or known contrast allergy are unlikely to benefit or are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Elderly patients with coronary disease often have chronic kidney disease and are at risk for contrast‑induced acute kidney injury (CI‑AKI) after percutaneous coronary intervention. This randomized interventional study compares tailored hydration guided by the Remote Dielectric Sensing (ReDS) lung‑water index versus standard hydration in patients scheduled for coronary intervention. The ReDS device is used to dynamically monitor lung water and adjust infusion rates to avoid fluid overload and acute pulmonary edema while providing necessary hydration. Outcomes include perioperative CI‑AKI, acute pulmonary edema, and longer‑term major cardiovascular events and need for hemodialysis.
Why it matters
Potential benefit: If successful, this approach could reduce contrast‑related kidney injury while lowering the risk of fluid‑overload complications like pulmonary edema.
How similar studies have gone: Personalized hydration strategies and various lung‑fluid monitoring approaches have shown promise in reducing CI‑AKI in some reports, but use of ReDS guidance for this indication is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 60 years; * Patients with unstable angina pectoris are scheduled for percutaneous coronary intervention; * Patients with chronic renal disease (estimated glomerular filtration rate \< 90 ml/min); * Sign the informed consent form. Exclusion Criteria: * 1\. Acute decompensated severe heart failure or cardiogenic shock; * 2\. Malignant tumors, severe renal failure (estimated glomerular filtration rate \< 30 ml/min); * 3\. Respiratory failure; * 4\. Used contrast media within one week; * 5\. Have allergic to contrast medium
Where it's running
-
Chinese PLA general hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Geng Qian, MD
- Email: qiangeng9396@263.net
- Phone: 086-010-55499209
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Managing multiple medications in older adults with chronic diseases
This project will see if taking many different medicines changes the health outlook of people aged 65 and older who have chronic conditions.
-
My Heart and CKD: A Shared Decision Aid to Help CKD and CAD Patients Choose Heart Procedures
A patient-focused online tool tests whether a personalized decision aid can help adults with chronic kidney disease and coronary artery disease make informed choices about heart procedures.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China
This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.